ImmunityBio, Inc.'s banner

ImmunityBio, Inc.

@ImmunityBio • 19,425 subscribers

ImmunityBio is developing cell and immunotherapy products that are designed to help strengthen patients’ natural immune system to fight cancer.

Shorts

ImmunityBio reported that median overall survival has not yet been reached in patients with recurrent or progressive glioblastoma treated with a chemo-free ANKTIVA® + CAR-NK-based regimen. As recent American Cancer Society data shows that brain cancer is now the third leading cause of cancer-related death among adults ages 20–49, these findings underscore the urgency of continued innovation in this disease. Read more:

ImmunityBio reported that median overall survival has not yet been reached in patients with recurrent or progressive glioblastoma treated with a chemo-free ANKTIVA® + CAR-NK-based regimen. As recent American Cancer Society data shows that brain cancer is now the third leading cause of cancer-related death among adults ages 20–49, these findings underscore the urgency of continued innovation in this disease. Read more:

107,245 görüntüleme

At ImmunityBio, we continue to prioritize long-term growth and the advancement of our broader immunotherapy platform. This additional non-dilutive financing supports our effort to expand globally with the goal of improving outcomes for patients. Read more:

At ImmunityBio, we continue to prioritize long-term growth and the advancement of our broader immunotherapy platform. This additional non-dilutive financing supports our effort to expand globally with the goal of improving outcomes for patients. Read more:

49,466 görüntüleme

Access to innovative cancer therapies continues to expand. ANKTIVA® is now available in Saudi Arabia for patients with bladder and lung cancers, marking an important step in ImmunityBio’s global efforts to reach more patients. Read more:

Access to innovative cancer therapies continues to expand. ANKTIVA® is now available in Saudi Arabia for patients with bladder and lung cancers, marking an important step in ImmunityBio’s global efforts to reach more patients. Read more:

31,946 görüntüleme

We're sharing our latest update, highlighting year-over-year revenue growth and financial metrics that support continued progress in our broader efforts. Access the full announcement:

We're sharing our latest update, highlighting year-over-year revenue growth and financial metrics that support continued progress in our broader efforts. Access the full announcement:

37,841 görüntüleme

We’ve reported ~700% year-over-year revenue growth, expanded ANKTIVA® authorizations in 33 countries, and continued progress in lung cancer. With additional label expansion plans and global commercialization efforts underway, we remain focused on broadening patient access worldwide. Read more:

We’ve reported ~700% year-over-year revenue growth, expanded ANKTIVA® authorizations in 33 countries, and continued progress in lung cancer. With additional label expansion plans and global commercialization efforts underway, we remain focused on broadening patient access worldwide. Read more:

57,481 görüntüleme

At ImmunityBio, our pipeline continues to expand with chemotherapy-free approaches designed to harness the power of one's own immune system. We have launched ResQ215B, a Phase 2 clinical study evaluating a novel chemotherapy-free and lymphodepletion-free combination immunotherapy in patients with indolent B-cell non-Hodgkin lymphoma (iNHL), including Waldenström’s Macroglobulinemia. Learn more:

At ImmunityBio, our pipeline continues to expand with chemotherapy-free approaches designed to harness the power of one's own immune system. We have launched ResQ215B, a Phase 2 clinical study evaluating a novel chemotherapy-free and lymphodepletion-free combination immunotherapy in patients with indolent B-cell non-Hodgkin lymphoma (iNHL), including Waldenström’s Macroglobulinemia. Learn more:

62,193 görüntüleme

We’ve announced a milestone in large-scale production and cryopreservation of memory cytokine-enhanced natural killer (NK) cells from more than 60 healthy and cancer donors, supporting ongoing research in NK cell–based therapies. Read more:

We’ve announced a milestone in large-scale production and cryopreservation of memory cytokine-enhanced natural killer (NK) cells from more than 60 healthy and cancer donors, supporting ongoing research in NK cell–based therapies. Read more:

36,011 görüntüleme

The NCCN® Clinical Practice Guidelines now include ANKTIVA® plus BCG for patients with BCG-unresponsive NMIBC with papillary-only disease. This update reflects continued progress in expanding treatment considerations for patients facing limited options following BCG therapy. Learn more:

The NCCN® Clinical Practice Guidelines now include ANKTIVA® plus BCG for patients with BCG-unresponsive NMIBC with papillary-only disease. This update reflects continued progress in expanding treatment considerations for patients facing limited options following BCG therapy. Learn more:

23,309 görüntüleme

This submission follows the FDA's review of additional data and represents an important regulatory step in expanding potential treatment options for adult patients with BCG-unresponsive NMIBC with papillary disease. Read more:

This submission follows the FDA's review of additional data and represents an important regulatory step in expanding potential treatment options for adult patients with BCG-unresponsive NMIBC with papillary disease. Read more:

21,864 görüntüleme

A step forward in global expansion: ANKTIVA® (nogapendekin alfa inbakicept-pmln) has received regulatory approval in Macau SAR, China for patients with BCG-unresponsive NMIBC ± CIS papillary tumors. Explore the full announcement:

A step forward in global expansion: ANKTIVA® (nogapendekin alfa inbakicept-pmln) has received regulatory approval in Macau SAR, China for patients with BCG-unresponsive NMIBC ± CIS papillary tumors. Explore the full announcement:

15,922 görüntüleme

ImmunityBio confirmed statistical power in our pivotal randomized trial evaluating ANKTIVA® + BCG versus BCG alone in BCG-naïve NMIBC, supporting the ability to detect clinically meaningful differences between treatment arms. This milestone builds on prior interim findings showing improved durability of complete response with ANKTIVA + BCG, reinforcing continued evaluation in earlier disease settings. Learn more:

ImmunityBio confirmed statistical power in our pivotal randomized trial evaluating ANKTIVA® + BCG versus BCG alone in BCG-naïve NMIBC, supporting the ability to detect clinically meaningful differences between treatment arms. This milestone builds on prior interim findings showing improved durability of complete response with ANKTIVA + BCG, reinforcing continued evaluation in earlier disease settings. Learn more:

11,424 görüntüleme

Today, the Saudi Food and Drug Authority (SFDA) granted accelerated approval of ANKTIVA® for use in combination with immune checkpoint inhibitors for adult patients with metastatic NSCLC whose disease has progressed following standard-of-care therapy. This marks the first approval anywhere in the world for ANKTIVA in this indication. Learn more:

Today, the Saudi Food and Drug Authority (SFDA) granted accelerated approval of ANKTIVA® for use in combination with immune checkpoint inhibitors for adult patients with metastatic NSCLC whose disease has progressed following standard-of-care therapy. This marks the first approval anywhere in the world for ANKTIVA in this indication. Learn more:

14,278 görüntüleme

Progress in non-muscle invasive bladder cancer (NMIBC) depends on continued innovation in how the disease is treated and managed over time. As patients and healthcare providers navigate complex care decisions, ImmunityBio is advancing new therapeutic approaches designed to support improved outcomes. Learn more:

Progress in non-muscle invasive bladder cancer (NMIBC) depends on continued innovation in how the disease is treated and managed over time. As patients and healthcare providers navigate complex care decisions, ImmunityBio is advancing new therapeutic approaches designed to support improved outcomes. Learn more:

11,092 görüntüleme